标题
HIF Inhibitors: Status of Current Clinical Development
作者
关键词
HIF, HIF inhibitor, Hypoxia inducible factor, Renal cell carcinoma, VEGF, VHL
出版物
Current Oncology Reports
Volume 21, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-02-12
DOI
10.1007/s11912-019-0752-z
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- SN-38 Acts as a Radiosensitizer for Colorectal Cancer by Inhibiting the Radiation-induced Up-regulation of HIF-1α
- (2018) TAKAYUKI OKUNO et al. ANTICANCER RESEARCH
- Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma
- (2018) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma
- (2018) Xiaomeng Dai et al. Translational Oncology
- Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin
- (2018) Zhao-jia Gao et al. MEDICAL SCIENCE MONITOR
- The prognosis outcome of oral squamous cell carcinoma using HIF-2α
- (2017) Elva Lim et al. Journal of the Chinese Medical Association
- Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma
- (2017) David Kung-Chun Chiu et al. Nature Communications
- Expression of HIF-1α in medullary thyroid cancer identifies a subgroup with poor prognosis
- (2017) Lutske Lodewijk et al. Oncotarget
- Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial
- (2016) S. M. Keefe et al. ANNALS OF ONCOLOGY
- A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
- (2016) Eli M. Wallace et al. CANCER RESEARCH
- Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel–Lindau Gene Mutation Status
- (2016) Yosra Messai et al. EUROPEAN UROLOGY
- PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma
- (2016) Melanie Ruf et al. INTERNATIONAL JOURNAL OF CANCER
- HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer
- (2016) Jian Yang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
- (2016) Caroline Wigerup et al. PHARMACOLOGY & THERAPEUTICS
- Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression
- (2016) Terumasa Sowa et al. Cancer Medicine
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- (2015) Lee M Krug et al. LANCET ONCOLOGY
- Hypoxia-induced autophagy contributes to the invasion of salivary adenoid cystic carcinoma through the HIF-1α/BNIP3 signaling pathway
- (2015) HAIWEI WU et al. Molecular Medicine Reports
- HIF-1α/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer
- (2015) YI SUN et al. ONCOLOGY REPORTS
- Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma
- (2015) Tiansuo Zhao et al. Oncotarget
- A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- (2014) Michinori Ogura et al. BRITISH JOURNAL OF HAEMATOLOGY
- Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
- (2014) Dali Zhao et al. CELLULAR SIGNALLING
- Prognosis value of HIF-1α expression in patients with non-small cell lung cancer
- (2014) Qian Wang et al. GENE
- Phase II trial of vorinostat in advanced melanoma
- (2014) N. B. Haas et al. INVESTIGATIONAL NEW DRUGS
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- HIF-1 - and hypoxia-dependent immune responses in human CD4+CD25high T cells and T helper 17 cells
- (2014) T. Bollinger et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival
- (2014) H Choudhry et al. ONCOGENE
- Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer
- (2013) Christopher R. Garrett et al. CANCER
- Overexpression of HIF-1α indicates a poor prognosis in tongue carcinoma and may be associated with tumour metastasis
- (2013) YANG ZHENG et al. Oncology Letters
- Resistance and Escape From Antiangiogenesis Therapy: Clinical Implications and Future Strategies
- (2012) Justin N. Bottsford-Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Passing the baton: the HIF switch
- (2012) Mei Yee Koh et al. TRENDS IN BIOCHEMICAL SCIENCES
- HIF-1α Confers Aggressive Malignant Traits on Human Tumor Cells Independent of Its Canonical Transcriptional Function
- (2011) Young-Gun Yoo et al. CANCER RESEARCH
- Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma
- (2011) Yasuhiro Oki et al. LEUKEMIA & LYMPHOMA
- HIF-1-Dependent Stromal Adaptation to Ischemia Mediates In Vivo Tumor Radiation Resistance
- (2011) D. L. Schwartz et al. MOLECULAR CANCER RESEARCH
- A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors
- (2010) Matthew H. Kulke et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate
- (2010) Justine Yang Bruce et al. INVESTIGATIONAL NEW DRUGS
- A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)
- (2010) Michael R. Harrison et al. INVESTIGATIONAL NEW DRUGS
- HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment
- (2010) Cesar A. Corzo et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Activity of 2 methoxyestradiol (Panzem ® NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: A Hoosier Oncology Group trial
- (2009) Daniela Matei et al. GYNECOLOGIC ONCOLOGY
- Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
- (2009) Evanthia Galanis et al. JOURNAL OF CLINICAL ONCOLOGY
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
- (2008) Rose Du et al. CANCER CELL
- A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer
- (2008) E. I. Heath et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More